Nventa Wins European Patent Challenge

SAN DIEGO, CA - Nventa Biopharmaceuticals Corporation announced in a Tuesday press release that it has received a favorable decision from the Technical Board of Appeal of the European Patent Office (EPO) for the company’s European Patent Number 1,002,110.

This patent, which allows exclusively through 2018, covers compositions of fusion proteins comprised of a human papillomavirus (HPV) antigen fused to a heat shock protein (Hsp), as well as DNA encoding such fusion proteins.

This decision dismisses an appeal announced on January 30, 2006, and upholds the EPO Opposition Division’s favorable decision of October 2005.

"We are very pleased with the Technical Board's decision to once again uphold this important European patent," Nventa President and CEO Gregory McKee said.

"This favorable ruling reaffirms the strength of our Intellectual Property portfolio and reinforces an important composition-of-matter patent covering our lead product candidate, HspE7, and other future therapeutics for HPV-related diseases and cancer," he continued.

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by HPV.

The company’s lead product candidate, HspE7, is a novel therapeutic candidate intended for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world.